Home
NewsNewsUNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
One of North Carolina’s leading providers when it comes to fertility treatment and care, UNC Fertility, on February 11, 2026, went ahead and announced its plans to expand to accommodate the growing demand from the growing population of the state and form a new collaboration with IVI RMA North America, which is one of the leading providers in terms of reproductive medicine services in the country.
The Raleigh location of the clinic has gone on to hire many new providers and is also looking to accommodate plans to open some more locations all across the state in a matter of time. The collaboration with IVI RMA North America will bring clinical and operational best practices for patient service in the Triangle and the surrounding region. IVI RMA Global, which is the parent company, goes on to offer reproductive medicine services in 15 countries with over 200 locations.
UNC Health’s Division Chief of Reproductive Endocrinology and Infertility and Medical Director at UNC Fertility, Dr. Colleen Milroy, said that “UNC Fertility is proud to serve the more than 2.4 million residents of the Triangle. Our region is one of the fastest growing in the country, and its population deserves the best patient care. This partnership with IVI RMA will ensure UNC Fertility is well-positioned to scale access over time, adding more providers and locations and broadening the types of treatments available to meet the demands from our diverse and expanding population.”
Apparently, UNC Health is going to retain complete ownership of the UNC Fertility practice, with all the physicians and care providers to remain employees of UNC Health. The present patients of UNC Fertility are going to continue to see their already local, dedicated providers.
Moreover, IVI RMA, along with UNC Health, is going to work together to create new opportunities as far as joint research and education programs are concerned. As part of the agreement, IVI RMA is going to partner with UNC Fertility when it comes to UNC Reproductive Endocrinology and the Infertility Fellowship so as to prepare a diverse group of physicians and hence become reproductive endocrinology and infertility service leaders. It is well to be noted that IVI RMA brings in valuable experience due to its present partnership with fellowship programs from Harvard University School of Medicine as well as Thomas Jefferson University.
According to the CEO of IVI RMA North America, Lynn Mason, “It’s an honor to partner with a globally recognized academic medical center like UNC Health and build on their already exceptional clinical foundation and outcomes. We’re excited to work with UNC Fertility as their team continues to grow their presence in North Carolina and the surrounding regions. This partnership reflects our shared dedication to advancing patient care and inspiring future leaders in reproductive endocrinology.”
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.
